These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27826740)

  • 1. Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status.
    Swart T; Hurley MJ
    CNS Drugs; 2016 Dec; 30(12):1127-1135. PubMed ID: 27826740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower Affinity of Isradipine for L-Type Ca
    Ortner NJ; Bock G; Dougalis A; Kharitonova M; Duda J; Hess S; Tuluc P; Pomberger T; Stefanova N; Pitterl F; Ciossek T; Oberacher H; Draheim HJ; Kloppenburg P; Liss B; Striessnig J
    J Neurosci; 2017 Jul; 37(28):6761-6777. PubMed ID: 28592699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease.
    Liss B; Striessnig J
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():263-289. PubMed ID: 30625283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium, ageing, and neuronal vulnerability in Parkinson's disease.
    Surmeier DJ
    Lancet Neurol; 2007 Oct; 6(10):933-8. PubMed ID: 17884683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.
    Ilijic E; Guzman JN; Surmeier DJ
    Neurobiol Dis; 2011 Aug; 43(2):364-71. PubMed ID: 21515375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting calciumopathy for neuroprotection: focus on calcium channels Cav1, Orai1 and P2X7.
    Torres-Rico M; García-Calvo V; Gironda-Martínez A; Pascual-Guerra J; García AG; Maneu V
    Cell Calcium; 2024 Nov; 123():102928. PubMed ID: 39003871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.
    Wang QM; Xu YY; Liu S; Ma ZG
    Oncotarget; 2017 Jul; 8(29):47284-47295. PubMed ID: 28521299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial.
    Parkinson Study Group STEADY-PD III Investigators
    Ann Intern Med; 2020 May; 172(9):591-598. PubMed ID: 32227247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease.
    Chan CS; Gertler TS; Surmeier DJ
    Mov Disord; 2010; 25 Suppl 1():S63-70. PubMed ID: 20187241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study.
    Simuni T; Borushko E; Avram MJ; Miskevics S; Martel A; Zadikoff C; Videnovic A; Weaver FM; Williams K; Surmeier DJ
    Mov Disord; 2010 Dec; 25(16):2863-6. PubMed ID: 20818667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).
    Parkinson Study Group
    Mov Disord; 2013 Nov; 28(13):1823-31. PubMed ID: 24123224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease.
    Surmeier DJ; Nguyen JT; Lancki N; Venuto CS; Oakes D; Simuni T; Wyse RK
    Mov Disord; 2022 Feb; 37(2):334-342. PubMed ID: 34766657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials.
    Rees K; Stowe R; Patel S; Ives N; Breen K; Ben-Shlomo Y; Clarke CE
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008535. PubMed ID: 22071852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of isradipine, an L-type calcium channel blocker on permanent and transient focal cerebral ischemia in spontaneously hypertensive rats.
    Campbell CA; Mackay KB; Patel S; King PD; Stretton JL; Hadingham SJ; Hamilton TC
    Exp Neurol; 1997 Nov; 148(1):45-50. PubMed ID: 9398449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease.
    Venuto CS; Yang L; Javidnia M; Oakes D; James Surmeier D; Simuni T
    Ann Clin Transl Neurol; 2021 Mar; 8(3):603-612. PubMed ID: 33460320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease.
    Cronin A; Grealy M
    Neuroscience; 2017 Dec; 367():34-46. PubMed ID: 29079063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-Modifying Drugs in Parkinson's Disease.
    Park A; Stacy M
    Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Trial Highlights: Phase III Study in Spotlight.
    McFarthing K; Simuni T
    J Parkinsons Dis; 2019; 9(1):3-4. PubMed ID: 30741695
    [No Abstract]   [Full Text] [Related]  

  • 19. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?
    Youdim MB; Geldenhuys WJ; Van der Schyf CJ
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S281-91. PubMed ID: 18267251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
    Chang CC; Cao S; Kang S; Kai L; Tian X; Pandey P; Dunne SF; Luan CH; Surmeier DJ; Silverman RB
    Bioorg Med Chem; 2010 May; 18(9):3147-58. PubMed ID: 20382537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.